HIV-1 resistance to the gp41-dependent fusion inhibitor C-34

Antiviral Research

Volumn 59, Issue 2, 2003, Pages 137-142

  Armand Ugón, Mercedes ^a   Gutiérrez, Arantxa ^a   Clotet, Bonaventura ^a   Esté, José A ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Fusion inhibitor; gp41; Heptad repeat; HIV 1; Resistance

Indexed keywords

ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMINO ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; DEXTRAN SULFATE; GLYCOPROTEIN GP 41; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0042706375     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(03)00071-8     Document Type: Article

References (24)

1. Armand-Ugon M., Quiñones-Mateu M.E., Gutierrez A., Barretina J., Blanco J., Schols D., De Clercq E., Clotet B., Esté J.A. Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antivir. Ther. 8:2003;1-8.
2. Barretina J., Blanco J., Armand-Ugón M., Gutiérrez A., Clotet B., Esté J.A. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antivir. Ther. 8:2003;155-161.
3. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:1997;7478-7487.
4. + T cell death during human immunodeficiency virus infection in vitro. Virology. 285:2001;356-365.
5. Cabrera C., Witvrouw M., Gutierrez A., Clotet B., Kuipers M.E., Swart P.J., Meijer D.K., Desmyter J., De Clercq E., Esté J.A. Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4. AIDS Res. Hum. Retroviruses. 15:1999;1535-1543.
6. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15613-15617.
7. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
8. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell. 93:1998;681-684.
9. Derdeyn C.A., Decker J.M., Sfakianos J.N., Zhang Z., O'Brien W.A., Ratner L., Shaw G.M., Hunter E. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75:2001;8605-8614.
10. Doranz B.J., Grovit-Ferbas K., Sharron M.P., Mao S.H., Goetz M.B., Daar E.S., Doms R.W., O'Brien W.A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186:1997;1395-1400.
11. Eckert D.M., Kim P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U.S.A. 98:2001;11187-11192.
12. Esté J.A. HIV resistance to entry inhibitors. AIDS Rev. 3:2001;121-132.
13. Esté J.A., Schols D., De Vreese K., Van Laethem K., Vandamme A.M., Desmyter J., De Clercq E. Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Mol. Pharmacol. 52:1997;98-104.
14. Folks T.M., Powell D., Lightfoote M., Koenig S., Fauci A.S., Benn S., Rabson A., Daugherty D., Gendelman H.E., Hoggan M.D. Biological and biochemical characterization of a cloned Leu-3-cell surviving infection with the acquired immune deficiency syndrome retrovirus. J. Exp. Med. 164:1986;280-290.
15. Freed E.O., Martin M.A. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J. Biol. Chem. 270:1995;23883-23886.
16. Jiang S., Zhao Q., Debnath A.K. Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des. 8:2002;563-580.
17. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1998;1302-1307.
18. Kliger Y., Gallo S.A., Peisajovich S.G., Munoz-Barroso I., Avkin S., Blumenthal R., Shai Y. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post lipid mixing stage. J. Biol. Chem. 276:2001;1391-1397.
19. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1995;1075-1082.
20. Meynard J.L., Vray M., Morand-Joubert L., Race E., Descamps D., Peytavin G., Matheron S., Lamotte C., Guiramand S., Costagliola D., Brun-Vézinet F., Clavel F., Girard P.M. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 16:2002;727-736.
21. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods. 20:1988;309-321.
22. Rimsky L.T., Shugars D.C., Matthews T.J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:1998;986-993.
23. Sista P., Melby T., Greenberg M., Davidson D., Jim L., Mosier S., Mink M., Nelson E., Fang L., Cammack N., Salgo M., Matthews T.J. Characterization of baseline and treatment-emergent resistance to T-20 (Enfuvirtide) observed in phase III clinical trials: substitutions in gp41 amino acids 36-45 and Enfuvirtide susceptibility of virus isolates. Antivir. Ther. 7:2002;S16.
24. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:2002;1896-1905.